UNMC Second Quarter Research Grants Total $9.7 Million

The University of Nebraska Medical Center received $9.7 million in federal

research grants during the second quarter of fiscal year 2003-2004. The

second quarter included the months of October, November and December.

As of February 2004, the universitys annual funding from the National

Institutes of Health is $44.3 million, said Thomas Rosenquist, Ph.D.,

vice chancellor for research. In the past two years, our NIH funding has

increased by more than 40 percent, going from $30 million to $44.3 million.

This is an exciting trend for UNMC since NIH funding is considered the

gold standard for research funding. UNMC is fortunate to have a growing

corps of investigators whose work attracts this prestigious funding. This

puts us on pace to meet our goal of $50 million in annual NIH funding by

the end of fiscal year 2004-2005.

In addition, our record-breaking pace for extramural funding continues,

following our $26 million first quarter for this fiscal year. The second

quarter is similar to last years but we anticipate an excellent third

quarter, based upon the large number of new research grant proposals that

were submitted by our energized research force.

Dr. Rosenquist said the new $77 million Durham Research Center is now

open and many investigators have moved into the lower levels. The new facility

will allow researchers to better collaborate on research projects and should

greatly enhance UNMCs research efforts, he said.

Some of UNMCs research highlights during the second quarter included:

Kristine McVea, M.D., associate professor in the department of family

medicine, received $485,550 to train teen peer group counselors for smoking

cessation. Teen smoking is a significant cancer control problem that is

currently not being addressed adequately, Dr. McVea said. Although 75 percent

of high school smokers have tried to quit, almost all interventions designed

to help teens break their habit have failed simply because teens do not

seek help.

In preliminary studies, peer counseling intervention has shown great

promise. Project staff members give four hours of training to teen peer

counselors who then deliver supportive, respectful smoking cessation messages

to their friends at school.  The project goal is to do a randomized,

controlled trial to test teen counseling effectiveness in 24 schools in

eastern Nebraska and western Iowa over the next three years.

Surinder Batra, Ph.D., professor, department of biochemistry and molecular

biology, received $310,000 to study how the bodily absorption, distribution,

metabolism and excretion of drugs with genetically-engineered antibodies

are affected when the drugs are used to increase the penetration of cancer

fighting antibodies into tumors. The use of surgery, radiation and chemotherapy

either alone or in combination has met with only modest success for advanced

cancer, Dr. Batra said. Radio immunotherapy (RAIT) is a smart way of

delivering radiation to cancer cells and is independent of drug toxicity

and/or hormone resistance. But even targeted RAIT has met with limited

success against advanced tumors. One form of therapy has been demonstrated

to improve the efficiency of RAIT, but its use is limited by its high systemic

toxicity. Dr. Batras study explores how to enhance vascular and tumor

penetration while minimizing the harmful potential from toxicity.

Bela Toth, DVM, professor at the Eppley Institute, received $220,000

to study the use of extract from the CV mushroom in the treatment of gastrointestinal

cancer a therapy already approved in Japan. Recently, hot water extracts

from the CV mushroom have been used as nutritional supplements by cancer

patients in the United States. Dr. Toths study will compare the bioactivity

of the clinical preparation to the nutritional supplement to better understand

the CV mushrooms ability to boost the immune system.  His project

seeks to prove that the extract can enhance the immune system and lead

to preventative and therapeutic activity in mice with colorectal cancer.

John Davis, Ph.D., professor in the department of obstetrics and gynecology,

and director of research and development for the Olson Center for Womens

Health, received $121,074 to study how primary cells will provide information

on the cellular events that control survival and proliferation of ovarian

cells. This information is expected to translate into more effective treatments

for enhancing reproductive potential in domestic farm animals. This research

may also provide insight into abnormal conditions such as premature ovarian

failure, ovarian disease and cell tumors of the ovary.

Gloria Borgstahl, Ph.D., associate professor at the Eppley Institute,

received $104,964 to develop a picture of what protein machines look like

in order to understand how they work and how to fix them when they are

broken. DNA the biological molecule that holds the genetic code encodes

all the proteins used by the cell. When the DNA becomes damaged, the resulting

proteins are abolished or become nonfunctional. Disease can result when

proteins responsible for repairing damaged DNA are not working properly.

The pathway of DNA repair studied in this project is thought to be of particular

relevance to breast cancer.